About Takeda Pharmaceuticals
Takeda Pharmaceuticals is a Healthcare company based in Dublin (Ireland) founded in 1986, and was acquired by Takeda in May 2018. Rare disease treatments are developed by a specialty biopharmaceutical firm. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Takeda Pharmaceuticals has raised $17 million across 2 funding rounds from investors including Takeda Pharmaceuticals. Takeda Pharmaceuticals has completed 16 acquisitions, including Advanced BioHealing, Baxalta and Bikam Pharmaceuticals. Its Indian entity Shire Biotech India Private Limited reported revenue of ₹13.91 Cr. Takeda Pharmaceuticals offers products and services including Oveporexton (TAK-861), Plasma-Derived Therapies, and Vaccines. Its focus areas include Pharmaceuticals, Biopharmaceuticals, Biotechnology and Rare Disease Treatments.
Company details
Takeda Pharmaceuticals is involved in the research, development, and manufacturing of innovative medicines. The company focuses on areas such as gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Solutions are provided to address unmet medical needs across various sectors, aiming to improve health outcomes and transform lives worldwide. Operations span multiple countries, ensuring a broad impact on global health systems.
- Headquarters Dublin, Ireland
- Stage Acquired
- SectorsHealthcare
- Website shire.com
- Social LinkedIn YouTube
- Acquired by Takeda (May 2018)
- Legal Name Takeda Pharmaceutical Company Limited
- Date of Incorporation 22 Sep, 2017
- Jurisdiction Gurgaon, Haryana, India
- Indian entity revenue₹13.91 Cr
FY 2022 · +24% YoY
- Indian entity net profit₹4.1 Lakh
FY 2022 · 0% margin
- Indian entity EBITDA₹6.4 Lakh
FY 2022 · 0% margin
- Total Equity Funding$17M (USD)
in 2 rounds
- Latest Funding Round$15M (USD), Series B
Oct 2013
- Investors
- Investments & AcquisitionsAdvanced BioHealing
& 15 more
- Acquired byTakeda
(May 2018)
Associated legal entities of Takeda Pharmaceuticals
Takeda Pharmaceuticals operates through Shire Biotech India Private Limited (amalgamated). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2022) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Shire Biotech India Private Limited CIN U51909HR2017FTC070872 | Amalgamated | 22 Sep 2017 | Gurgaon, Haryana | ₹13.9 Cr | 4 | View details |
Products & Services of Takeda Pharmaceuticals
Takeda Pharmaceuticals offers a comprehensive portfolio of products and services, including Oveporexton (TAK-861), Plasma-Derived Therapies, and Vaccines.
Developed for treating Narcolepsy Type 1 patients.
Innovated for rare and complex chronic diseases.
Created to address global infectious disease needs.
Apps and channels of Takeda Pharmaceuticals
Takeda Pharmaceuticals publishes 1 mobile app with over 100 downloads; its YouTube channel Takeda has 23.6K subscribers and 30 videos.
Videos from Takeda Pharmaceuticals
The most watched videos on Takeda Pharmaceuticals's YouTube channel, Takeda (23.6K subscribers). Click a video to play it here.
More on Takeda.
Funding Insights of Takeda Pharmaceuticals
Takeda Pharmaceuticals has successfully raised a total of $17M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17M
- Total Rounds 2
- Last Round Series B — $15M
- First Round $2M
(Jul 2011)
All 2 funding rounds of Takeda Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2013 | $15M | Series B | – | – | – |
| Jul 2011 | $2M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Takeda Pharmaceuticals
Takeda Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for Takeda Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Shire Biotech India Private Limited (Takeda Pharmaceuticals)
Shire Biotech India Private Limited is the primary company behind Takeda Pharmaceuticals. The board of Shire Biotech India Private Limited currently have 4 directors; the longest-serving is Gopal Agrawal, appointed in 2019. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Gopal Agrawal DIN 08532882 | Director | 08 Aug 2019 | 7 yrs 3 mo | Shire Biotech India Private Limited |
| Anoop Kishore Kamat DIN 09158117 | Director | 23 Apr 2021 | 5 yrs 6 mo | Shire Biotech India Private Limited |
| Rajesh Eric Dmellokamath DIN 09245406 | Director | 31 Jul 2021 | 5 yrs 3 mo | Shire Biotech India Private Limited |
| Serina Magner Fischer DIN 09534518 | Director | 16 Mar 2022 | 4 yrs 7 mo | Shire Biotech India Private Limited |
People of Takeda Pharmaceuticals
1052 people are tracked at Takeda Pharmaceuticals (634 in leadership, 11 in board & advisors, 407 in team).
| Name | Role | Group |
|---|---|---|
Petr Galík | TBS Global Head Of Innovation, Analytics And Automation | Leadership |
Andrew S. Plump | Director, President of Research & Development | Leadership |
Manan Shah | Associate Director Global CMC Regulatory Affairs | Leadership |
Sridevi Ponduru M.D. | Senior Medical Director | Leadership |
Milano Furuta | CFO | Leadership |
Michael Denne | VP US Medical Affairs, Rare Disease And Plasma Derived Therapies | Leadership |
Neeraj Gupta | Executive Director And Head | Leadership |
Teresa Bitetti | President, Global Oncology | Leadership |
Giuseppe Piergiovanni | Head Of Process Engineering For Plasma | Leadership |
Dominic Cirincione | Associate Director, US Advertising And Promotion Regulatory (a&p Excellence) | Leadership |
Simeon William | Senior Human Resource Business Partner - India | Leadership |
Luna Zaru | Director | Leadership |
Julie Kim | Interim Head, Global Portfolio Division | Leadership |
Masato Iwasaki | President, Japan Pharma | Leadership |
Kristi Bond | Media Relations & Operations Head | Leadership |
Krystal Sing | Medical Director | Leadership |
Eileen Burkart Hartman | Senior Director, US Medical Office, Scientific Communications | Leadership |
Russ Gaszak | Head Of Sales - Neuroscience | Leadership |
Lauren Duprey | Chief Human Resources Officer | Leadership |
Nereyda Garcia | Head, Ethics & Compliance, US Business Unit | Leadership |
1032 more people are available in the full profile.
Complete people profiles for Takeda Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Takeda Pharmaceuticals
Figures of Shire Biotech India Private Limited, the primary company behind Takeda Pharmaceuticals, for FY 2022. Revenue was ₹13.91 Cr (+24% year on year). Net profit was ₹4.1 Lakh (0% margin). EBITDA was ₹6.4 Lakh (0% margin).
- ₹13.91 CrRevenue · FY 2022 · +24% YoY
- ₹4.1 LakhNet profit · 0% margin
- ₹6.4 LakhEBITDA · 0% margin
- ₹1 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Shire Biotech India Private Limited are on its company page.
Detailed financial statements for Takeda Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Takeda Pharmaceuticals
Takeda Pharmaceuticals has strategically engaged in corporate development activities, having acquired 16 companies. Notable acquisitions include Advanced BioHealing, Baxalta and Bikam Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Blood plasma donation and collection services are provided. | sanaplasma.com | Osaka, Japan | 2006 | Sep 2018 | •••• | |
Developer of therapies for orphan diseases and other disease conditions | baxalta.com | Chicago, United States | 2015 | Jan 2016 | $32B | |
Speciality biopharma company developing novel therapeutics for rare diseases | dyax.com | Burlington, United States | 1995 | Nov 2015 | $6.6B | |
Therapies in ophthalmology and otolaryngology are developed using PVP-I technology. | foresightbio.com | New York, United States | 2008 | Aug 2015 | $300M | |
Phase III-ready rare disease drug for gastrointestinal and atopic diseases | meritagepharma.com | San Diego, United States | 2008 | Feb 2015 | $245M | |
Biopharmaceutical treatments for rare gastrointestinal and endocrine disorders are developed. | npsp.com | Bedminster, United States | 1986 | Jan 2015 | •••• | |
Small molecule therapeutics for degenerative eye diseases were developed. | bikampharmaceuticals.com | Cambridge, United States | 2007 | Jul 2014 | •••• | |
Passionately pursuing better treatments for adults and children with rare liver diseases. | lumenapharma.com | San Diego, United States | 2011 | May 2014 | $260M | |
Drugs for fibrosis prevalent in chronic kidney disease and heart failure | fibrotech.com.au | Melbourne, Australia | 2006 | May 2014 | $75M | |
Therapies for viral and other infectious diseases | viropharma.com | Exton, United States | 1994 | Nov 2013 | $4.2B |
Complete acquisition details for Takeda Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Takeda Pharmaceuticals
15 dated milestones of Takeda Pharmaceuticals across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Takeda Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series B, of $15.0M.
- Acquisition Acquires ViroPharma.
- Acquisition Acquires Fibrotech Therapeutics.
- Acquisition Acquires Lumena Pharma.
- Acquisition Acquires Bikam Pharmaceuticals.
- Acquisition Acquires NPS Pharma.
- Acquisition Acquires Meritage Pharma.
- Acquisition Acquires Foresight Biotherapeutics.
- Acquisition Acquires Dyax.
- Acquisition Acquires Baxalta.
- Exit Acquired by Takeda.
- Acquisition Acquires Sanplasma.
Web traffic of Takeda Pharmaceuticals
The website of Takeda Pharmaceuticals (shire.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 75.2% vs previous month
Websites whose visitors overlap most with Takeda Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vrtx.com | 100% | 342.2K | #151,023 | View details | |
shirepharmaceuticals.co.uk | shirepharmaceuticals.co.uk | 100% | – | ||
| neurocrine.com | 99% | 39.1K | #927,855 | View details | |
| pfizer.com | 99% | 1.9M | #24,984 | View details | |
shirecanada.com | shirecanada.com | 84% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Takeda Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Takeda Pharmaceuticals
Complete news archive for Takeda Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Takeda Pharmaceuticals
Takeda Pharmaceuticals was founded in 1986 and raised its 1st funding round 25 years after it was founded.
Takeda Pharmaceuticals is headquartered in Dublin, Ireland.
Takeda Pharmaceuticals is a funded company, having raised a total of $17M across 2 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Jul 2011.
The primary company behind Takeda Pharmaceuticals, Shire Biotech India Private Limited, reported revenue of ₹13.91 Cr for FY 2022, up 24% year on year.
Takeda Pharmaceuticals is involved in the research, development, and manufacturing of innovative medicines. The company focuses on areas such as gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Solutions are provided to address unmet medical needs across various sectors, aiming to improve health outcomes and transform lives worldwide. Operations span multiple countries, ensuring a broad impact on global health systems.
Takeda Pharmaceuticals offers Oveporexton (TAK-861), Plasma-Derived Therapies, and Vaccines.
Takeda Pharmaceuticals has made 16 acquisitions, including Advanced BioHealing, Baxalta, and Bikam Pharmaceuticals.
Takeda Pharmaceuticals has 1 investor. Key investors include Takeda Pharmaceuticals.
Takeda Pharmaceuticals operates through Shire Biotech India Private Limited.
Yes. Takeda Pharmaceuticals was acquired by Takeda in May 2018.
The legal entities of Takeda Pharmaceuticals currently have 4 directors, including Anoop Kishore Kamat, Rajesh Eric Dmellokamath, Gopal Agrawal and others.
Yes. Takeda Pharmaceuticals publishes myPNtracker, with over 100 downloads.